Scandion Oncology Company Description

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer.

Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer.

The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV.

The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.

Scandion Oncology A/S

Country	Denmark
Founded	2017
Industry	Biotechnology
Sector	Healthcare
Employees	4
CEO	Francois Martelet

Contact Details

Address: Symbion Copenhagen, 2100 Denmark
Phone	45 38 10 20 17
Website	scandiononcology.com

Stock Details

Ticker Symbol	SCOL
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	DKK
ISIN Number	DK0061031895
SIC Code	2836

Key Executives

Name	Position
Dr. Francois Regis Martelet M.D.	Chief Executive Officer
Jan Stenvang M.S., Ph.D.	Chief Scientific Officer
Johnny Stilou M.S.	Chief Financial Officer
Morten Nissen	General Counsel
Mads Kronborg	Head of External Communication